Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Aetna Insurance
Vincristine Sulfate Liposome Injection (Marqibo)
Policy
Aetna considers vincristine sulfate liposome injection (Marqibo) medically necessary for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL) as a single-agent therapy when either of the following criteria is met:
Member has Philadelphia chromosome-negative ALL; or
Member has Philadelphia chromosome-positive ALL refractory to tyrosine kinase inhibitors (TKIs).
Aetna considers continuation of vincristine sulfate liposome injection (Marqibo) medically necessary for members with ALL meeting initial selection criteria, and when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.
Aetna considers vincristine sulfate liposome injection experimental and investigational for all other indications, including the following (not an all-inclusive list) because its effectiveness for these indications has not been established:
Acute myeloid leukemia
Adrenal cortical carcinoma
AIDS-related Kaposi's sarcoma
Anaplastic large cell lymphoma
Angioimmunoblastic T-cell lymphoma
Bone cancer
Breast cancer
Breast cancer brain metastases
Choroid plexus tumors
Chronic myelogenous leukemia
Ependymoma
Ewing's sarcoma
Glioma
Hodgkin lymphoma
Kidney cancer
Lung cancer
Melanoma
Multiple myeloma
Neuroblastoma
Non-Hodgkin’s lymphoma
Oral mucositis
Peripheral T-cell lymphoma
Pleuropulmonary blastoma
Primitive neuroectodermal tumor
Retinoblastoma
Rhabdomyosarcoma
Soft tissue sarcoma
Uveal melanoma
Wilms tumor.
Policy History
Last Reviewopens in a new browser pop-up window 12/02/2020
Effective: 07/19/2016
Next Review: 08/12/2021
http://www.aetna.com/cpb/medical/data/900_999/0908.html
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159015097
Thank-You my good Friend!!
You know I lost two to cancer/ My sister and my wife of three years only married when I was young.
Thank-You for remembering my friend it's was June 8th 2019!! It's always a very hard day!! and today Memorial Day!! :(
A virosome is an innovative hybrid drug delivery system with advantages of both viral and non-viral vectors. Studies have shown that a virosome can carry various biologically active molecules, such as nucleic acids, peptides, proteins and small organic molecules. Targeted drug delivery using virosome-based systems can be achieved through surface modifications of virosomes. A number of virosome-based prophylactic and therapeutic products with high safety profiles are currently available in the market. Cancer treatment is a big battlefield for virosome-based drug delivery systems. This review provides an overview of the general concept, preparation procedures, working mechanisms, preclinical studies and clinical applications of virosomes in cancer treatment.
https://hrcak.srce.hr/128998
Mochtar Riady Institute
mrinstitute.org › Research › nav2d
NDV virosome for brain tumor therapy.. Brain cancer has become concern because of their rapid development and the treatments are often fail, so that new treatment strategy is an urge. Virosome is viral vector without genetic material and composed of phospholipid bilayer and surface glycoprotein.
http://mrinstitute.org/Research/nav2d.html
This is a big deal my sister died of Brain Cancer!!! Get it done RK!!
Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment
https://pubmed.ncbi.nlm.nih.gov/26011928/
BIG DEAL WHEN IT COMES ON ONCOLOGY!! GET IT DONE RK!!!!!!!!!
During her role as the head of non-clinical development at
Mymetics, a viral vaccine company, she also extended
and added to her expertise the production of biologics,
vaccines and ATMPs and the aspects of potency assays
and GMP
https://informaconnect.com/uploads/60-second-interview-Melody-Janssen--d23f4caea79d2bdcfe55d59228928124.pdf
MELODY JANSSEN
I chose to study “human biology” at the Philipps University of Marburg majoring in infectious diseases. My master thesis was based on work I had done with the Rift Valley Fever Virus in Canada under the supervision of Dr. Heinz Feldmann.
https://scipotconsultancy.com/my-story
For researchers such as Heinz Feldmann, a virologist at the US National Institute of Allergy and Infectious Disease (NIAID) in Hamilton, Montana, the situation seems like it could have been avoided. In 2005, he published a vaccine platform based on vesicular stomatitis virus (VSV) that has since yielded an Ebola vaccine that is effective in macaques (T. W. Geisbert et al. PLoS Med. 2, e183; 2005). But money is not available to take the next step — testing the vaccine’s safety in healthy humans, says Feldmann. Compared with malaria or HIV, “Ebola is just not that much of a public-health problem worldwide”, he says, and consequently draws little interest from public or private funders.
https://www.nature.com/news/ebola-treatments-caught-in-limbo-1.15634
Chimera Biotec your Quanterix Corporation Partner
Chimera Biotec MACIVIVA project with Mymetics
PD-L1, or “programmed-death ligand 1” (also known as
CD274 or B7-H1) is a membrane bound glycoprotein in the
B7 family of cell surface ligands involved in regulation of
the immune system. PD-L1 is expressed on a variety of
inflammatory-activated cells, some carcinomas, and in
melanoma (ovary, colon, lung, breast, and renal cell
carcinomas). PD-L1 expression on tumor cells is correlated
with poor prognosis in patients with cancers such as
NSCLC, esophageal cancer, and pancreatic carcinoma.
Levels of PD-L1 are increased in the plasma of cancer
patients as well as in cerebrospinal fluid of gliomas. sPDL1 is a biomarker of poor survival in patients with B cell
lymphoma, renal cell carcinoma, metastatic melanoma or
lung cancer, and is associated with advanced tumor stage.
PD-L1 contributes to immune evasion by binding to PD-1
and CD80 to suppress the activation and proliferation of T
cells and induce apoptosis of activated T cells. Blocking
the PD-1/PD-L1 pathway to prevent this immune evasion
and restore anti-tumor immunity has emerged as a
promising anti-cancer strategy
https://www.chimera-biotec.com/fileadmin/public/images/Datasheets/PD-L1_item_102648_Chimera.pdf
"Vaccination - No Cold Chain, No Needles" Chimera Biotech GmbH
Combining bridging and sandwich assay formats, custom developed for each analytical task on the ultra sensitive Immuno-PCR based Imperacer platform, we supported proof of concept preclinical studies and a clinical trial on HIV-1 mucosal virosome vaccination.
Virosomes are efficient antigen delivery vehicles. Their empty lumen lacks nucleic acid, making them non-infectious.
With the help of Chimera’s state-of-the art immunoassay analytics, virosomes displaying a particular HIV antigen structure, have been shown to increase mucosal antibodies blocking early transmission events. Since respiratory, genital and gastrointestinal mucosa are interconnected, NK cells, T and B lymphocytes can migrate and seed to distant mucosal tissue.
https://www.chimera-biotec.com/about-us/blog-news/
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162320862
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162313602
William DeGrado
https://en.wikipedia.org/wiki/William_DeGrado
Maria Rafalski's research while affiliated with University of Texas Southwestern Medical Center and other places
https://www.researchgate.net/scientific-contributions/Maria-Rafalski-5743281
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=162324983
Antonio Ortiz's research while affiliated with University of Groningen and other places
https://www.researchgate.net/scientific-contributions/Antonio-Ortiz-60375496
Biochemistry
. 1991 Oct 22;30(42):10211-20. doi: 10.1021/bi00106a020.
Membrane fusion activity of the influenza virus hemagglutinin: interaction of HA2 N-terminal peptides with phospholipid vesicles
M Rafalski 1, A Ortiz, A Rockwell, L C van Ginkel, J D Lear, W F DeGrado, J Wilschut
Affiliations collapse
Affiliation
DuPont-Merck Pharmaceutical Company, Wilmington, Delaware 19880-0328.
https://pubmed.ncbi.nlm.nih.gov/1931950/
Membrane Fusion Activity of Influenza Virus and Reconstituted Viral Envelopes (Virosomes)
Membrane Fusion Activity of Influenza Virus and Reconstituted ...
link.springer.com › chapter › 10
The DuPont-Merck Pharmaceutical Co. Wilmington USA; About this chapter. Cite this chapter as: Wilschut J. et al. (1991) Membrane Fusion Activity of Influenza Virus ...
Author: Jan Wilschut, Romke Bron, Jan Dijkstra, Antonio Ortiz, Lucina C. van Ginkel, William F. DeGrado, Mar...
Cited by:
https://link.springer.com/chapter/10.1007%2F978-3-0348-7454-0_23
The family of Thomas Staehelin, a Basel-based business lawyer, is behind uptown Basel, who wants to invest 400 to 500 million Swiss francs in their project. Uptown Basel is creating a smart manufactering hub for technology companies that want to network on the 70,000 square metre Schorenareal in Arlesheim. Space will be created for 2000 jobs.
https://www.nau.ch/ort/basel/ex-regierungsrat-baschi-durr-wird-chef-von-uptown-basel-65892506
BIG BONANZA??????????
https://upload.wikimedia.org/wikipedia/en/f/f1/Bonanza_title_screen.jpg
CpG Oligodeoxynucleotides and Interleukin-12 Improve the ...
www.researchgate.net › publication › 12547602_CpG_O
Jordi Torrelles; View ... Findings of the present study indicated that virosome formulations containing CpG-ODN were able to elicit significantly higher systemic and neutralizing antibody
https://www.researchgate.net/publication/12547602_CpG_Oligodeoxynucleotides_and_Interleukin-12_Improve_the_Efficacy_of_Mycobacterium_bovis_BCG_Vaccination_in_Mice_Challenged_with_M_tuberculosis
Professor Jordi B Torelles
Institute: Texas Biomedical Research Institute
https://www.hic-vac.org/members/members-profiles/professor-jordi-b-torelles
https://www.txbiomed.org/news-press/news-releases/texas-biomed-scientists-developing-new-vaccine-strategy-for-tuberculosis/
CpG oligodeoxynucleotides | Sigma-Aldrich
www.sigmaaldrich.com › catalog › search
Search results for CpG oligodeoxynucleotides at Sigma-Aldrich. Changes will be taking place on SigmaAldrich.com on June 5, 2021 that include visual and functional updates.
https://www.sigmaaldrich.com/catalog/papers/26346655
Background: An increasing number of tumor associated antigens (TAA) capable of inducing immune responses have been identified in the last two decades. Unfortunately, they are weak immunogens and require potent adjuvants to promote their immunogenicity. Virosomes, nano-lipid vesicles containing viral protein spikes, have been proven amenable for transferring antigen (Ag) to the major histocompatibility complex (MHC) class I processing pathway with the aim to prime cytotoxic T-ymphocytes (CTL) responses. Objective: This mini-review outlines the virosomes platform, ranging from virosomal preparation, their intracellular trafficking and mechanism of action. Methods: The review is directed toward an application of virosomes as a novel and potential vaccine adjuvant in active cancer immunotherapy. Results and conclusion: Virosomes have been proven to be a suitable TAA delivery carrier. Ag encapsulated inside the lumen of virosomes could be prevented from serum- and cell-associated peptidases. Virosomes also facilitated the intracellular trafficking of encapsulated Ag, in which Ag could reach the cytosol and be presented by the MHC-Class I machinery. In addition, virosomes with TAA encapsulated are amenable to be a novel tumor immunotherapeutic strategy.
https://www.researchgate.net/publication/228346372_Virosome_vaccines_and_their_application_in_cancer_immunotherapy
The objective of the project is to evaluate the suitability of Mymetics’ proprietary virosome vaccine delivery technology in combination with IO Biotech’s T-win® technology. IO Biotech will provide Mymetics with their proprietary peptide based antigen (Ag) which Mymetics will link to its virosome-based vaccine carrier and produce several formulations. IO Biotech will then compare, Ag-Virosomes, Ag alone, Virosomes alone to other control groups in a preclinical therapeutic tumor model.
https://www.cmocro.com/news_detail/Mymetics+Starts+Research+Project+in+Cancer+Immunotherapy+wit/495264/index.html
(PDF) Vaccine Strategies to Improve Anti-cancer Cellular ...
www.researchgate.net › publication › 330543268
Jan 22, 2019 · Virosomes and virus-like particles (VLP) are 20–100 nm size and consist of the membrane envelop of a. virus (including embedded proteins) but devoid of a replication- ... NCT03047928 Combination .
https://www.researchgate.net/publication/330543268_Vaccine_Strategies_to_Improve_Anti-cancer_Cellular_Immune_Responses
Clinical efficacy and immunity of combination therapy with ...
oncologypro.esmo.org › meeting-resources › esmo
ClinicalTrials.gov Identifier: NCT03047928 1 IO Biotech (www.iobiotech.com) has licensed the patent of the vaccine IO102/IO103 T-win®.
https://oncologypro.esmo.org/meeting-resources/esmo-virtual-congress-2020/clinical-efficacy-and-immunity-of-combination-therapy-with-nivolumab-and-ido-pd-l1-peptide-vaccine-in-patients-with-metastatic-melanoma-a-phase-i
Virosomes were widely utilized in cancer vaccines because they are incapable of replicating and therefore are not infectious but retain the ability of the parenting virus while carrying tumor-specific antigens to the APCs to induce immunity (174). Thus, virosomes increase the tumor-specific antibody and T cell responses (175, 176), as has been observed in phase I clinical trial on metastatic breast cancer patients (177, 178). The main advantages of virosomes as efficient prophylactic and therapeutic agents are tissue targeting, immune activation and potentiation. Application of virosomes in cancer vaccine will open a new prospective with multiple safe advantages as a unique delivery system (179–181). Recently, adding magnetic agents to HA-virosomes has been proposed as a ground-breaking innovative platform for treating cerebral tumors by enabling targeting using an external magnetic field from a magnetic helmet (182).
https://www.frontiersin.org/articles/10.3389/fimmu.2020.615240/full
New polypeptide could provide universal protection against coronaviruses – News-Medical.Net
Furthermore, the researchers say the polypeptide inhibitor – called F1 – is expected to be effective against the spike proteins of almost any SARS-CoV-2 variants that may emerge in the future. Said Jianpeng Ma/ From Baylor College of Medicine
https://covid19beinformed.com/index.php/2021/04/12/new-polypeptide-could-provide-universal-protection-against-coronaviruses-news-medical-net/
Untersuchungen zur F-proteinvermittelten Fusion von Paramyxoviren
www.researchgate.net › publication › 279826632
Both F1 and HA2 are formed by proteolytic cleavage of precursor glycoproteins (Fo, Sendai virus; HAo, influenza virus). ... Toon Stegmann; ... Polypeptide segments which insert into the apolar ...
Sendai Virosomes Revisited: Reconstitution with Exogenous ...
www.researchgate.net › publication › 12562128_Sendai
Toon Stegmann; Tobias Kamphuis; ... (F0), and the active, cleaved form (F1,2) have been compared. ... The inactive F0 bound an estimated 27 molecules of Triton X-100/F polypeptide; these molecules ...
GMP production services of recombinant vaccine candidates for clinical trials phase I/II
Description of service
GMP production of recombinant vaccine candidates for clinical trials phase I/II. SSI offers Manufacture of GMP master/working cell banks and manufacture of clinical-grade vaccine candidate (drug substance).
https://www.transvac.org/gmp-vaccine-clinical-trials
https://www.transvac.org/vaccine-development-services
https://www.transvac.org/Partners/Helmholtz-Centre-for-Infection-Research-(HZI)
Ingestible Osmotic Pill for In-vivo Sampling of Gut Microbiome
Hojatollah Rezaei Nejad, Bruno C. M. Oliveira, Aydin Sadeqi, Amin Dehkharghani, Ivanela
Kondova, Jan A.M. Langermans, Jeffrey S. Guasto, Saul Tzipori, Giovanni Widmer, Sameer R.
Sonkusale*
https://www.biorxiv.org/content/10.1101/690982v1.full.pdf
https://eatris.eu/people/jan-langermans/
https://eatris.eu/projects/transvac-2/
What's this all about? LMAO
Derrick Washington
Lead Cashier at Mymetics Corporation
Peoria, Illinois, United States Contact info
Mymetics Corporation
4 connections
Linkedin
https://www.linkedin.com/in/derrick-washington-300b79130/
Many thanks to a true MYMX investor, This is par nun that all us here share in the information brought forward for all of us. I think the company needs some lessons on sharing info to it's commons. Thank You Phosphene!! Anyone here on this board can be a voice!! :)
The partners in the project are Solvay Pharmaceuticals B.V., Nobilon International B.V., OctoPlus N.V., ViroClinics B.V., Virosome Biologicals B.V., the Erasmus University Medical Center Rotterdam, Leiden University, the University Medical Center Groningen, Utrecht University and the Netherlands Vaccine Institute.
https://www.biospace.com/article/releases/virosome-biologicals-b-v-release-a-large-scale-research-project-by-a-dutch-consortium-addressing-a-global-problem-/
Difference between MHC Class I and MHC Class II Proteins
November 27, 2017
Last updated on May 10th, 2021
Major Histocompatibility Complex (MHC) is a tightly linked cluster of genes present in every mammalian species. The MHC is referred to as the HLA complex in humans and the H-2 complex in mice.
https://microbeonline.com/difference-mhc-class-mhc-class-ii-proteins/
Professor
Biochemistry-Ma Lab
Baylor College of Medicine
Houston, TX US
Lodwick T. Bolin Professor in Biochemistry
Biochemistry
Baylor College of Medicine and Rice University
Houston, Texas United States
Member
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas United States
https://www.bcm.edu/people-search/jianpeng-ma-25834
https://profiles.viictr.org/display/BCM/jianpeng-ma
Jianpeng Ma
Adjunct Professor of Bioengineering & BioSciences, Rice University
Lodwick T. Bolin Professor of Biochemistry, Baylor College of Medicine
Bioengineering
CONTACT
(713) 798-8187 | jpma@bcm.tmc.edu
https://profiles.rice.edu/faculty/jianpeng-ma
New polypeptide could provide universal protection against coronaviruses – News-Medical.Net
Furthermore, the researchers say the polypeptide inhibitor – called F1 – is expected to be effective against the spike proteins of almost any SARS-CoV-2 variants that may emerge in the future. Said Jianpeng Ma/ From Baylor College of Medicine
https://covid19beinformed.com/index.php/2021/04/12/new-polypeptide-could-provide-universal-protection-against-coronaviruses-news-medical-net/
Initiated clinical trial with novel nasal spray codenamed APR-AOS2020 in patients with mild COVID-19
Thursday May 13, 2021 17:00 —PRNewswire Press Releases
Product recently cleared in EU as Class III medical device
About APR Applied Pharma Research s.a. ("APR")
APR is an independent pharma company headquartered in Switzerland with subsidiaries in Italy and Germany focused, since more than 25 years, in the development and commercialization of products intended to improve the quality of life of patients and families dealing with serious diseases of high medical need. APR's portfolio includes products for the treatment of rare or niche diseases which are commercialized in about 50 countries worldwide either directly or through licensing and distribution agreements with selected partners. The pipeline includes products at different stage of development concentrated in 3 selected therapeutic areas: inherited metabolic recessive diseases, cancer supportive care and skin rare diseases. For more information, please visit: https://www.apr.ch/
https://www.ryt9.com/en/anpi/249575
This product has been fast tracked by the FDa as a result of its astonishing effect on COVID-19 patients
Scientific Name: (Vasoactive intestinal peptide – Aviptadil) – VIP Nasal Spray
Clinical Test Expectation: Proven Covid-19 blocker, Covid19 critical recovery, gut repair, increases glycogenolysis, contractility in the heart, lowers arterial blood pressure, relaxes the smooth muscle of trachea, stomach and gallbladder. Regulates prolactin secretion, full balancing of circadian rhythm, can assist with osteoarthritis
MG Strength: 1mg per vial
Detailed Product Information
Function as COVID-19 aid.
https://peptidesworldwide.com/product/vip-nasal-peptide/
Continue from last post!
New polypeptide could provide universal protection against coronaviruses
By Sally Robertson, B.Sc. Apr 11 2021
“We expect the inhibitor reported here to be an invaluable aid to help end the COVID-19 pandemic,” writes Jianpeng Ma and colleagues from Baylor College of Medicine in Houston, Texas.
https://www.news-medical.net/news/20210411/New-polypeptide-could-provide-universal-protection-against-coronaviruses.aspx
The rgp41 polypeptide was found to be present in the supernatant. Therefore, the protein is
soluble. Example 5 Preparation of Virosome-Like Vesicles Presenting a gp41 Polypeptide
Produced in E. Coli on the External Surface (rgp41-Virosomes), and Preparation of Virosomes
Presenting a Synthetic Peptide on the External Surface (P1-Virosomes)
RGP41 POLYPEPTIDE MYMX PATENT
https://www.freepatentsonline.com/8765137.html
Treatment of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) with a Polypeptide
Treatment of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) with a Polypeptide
Case ID:
UA20-216
Invention:
SARS-CoV viruses bind to ACE2, a cell surface protein receptor. The ACE2 binding reduces the ability of ACE2 to break down Angiotensin-II (Ang-II). Ang-II is a potent vasoconstrictor that can increase lung injury and lung edema, increase blood pressure, and can be harmful to organ function at high concentrations.
This technology administers a polypeptide through a pharmaceutically acceptable salt form to patients infected with a SARS coronavirus. The polypeptide works to counteract the harmful effects of Ang-II and thus is an effective treatment for coronavirus symptoms. This substance is to be administered to the patient daily for at least one week to achieve the intended results.
Background:
In March 2020, SARS-CoV-2, a novel coronavirus, became a global pandemic and since then has infected more than 92 million people worldwide, killing nearly 2 million of those people. Even over a year since the first SARS-CoV-2 was reported, there are still very few treatment options available to counteract the negative effects of the viral infection. Therefore, it is imperative to develop effective treatments for SARS-CoV-2. This treatment also can be effective against other coronaviruses.
This treatment technology is rapidly metabolized in the blood into biologically active fragments and can be continuously infused by any suitable route that permits such continuous infusion, including intravenously. It can be used to treat a variety of symptoms of coronavirus infections by improving the functions of the lungs, kidneys, bone marrow, coagulation parameters, brain, and heart.
Applications:
Treatment for coronavirus infection, including SARS-CoV-2
Improves function of:
lungs, kidneys, bone marrow, coagulation parameters, brain, and heart
Counteracts harmful effects of increased concentrations of angiotensin II
https://inventions.arizona.edu/tech/Treatment_of_Severe_Acute_Respiratory_Syndrome_Coronavirus_(SARS-CoV)_with_a_Polypeptide
Baylor College Of Medicine
High-Potency Polypeptide-based Interference for Coronavirus Spike Glycoproteins
Jianpeng Ma, Adam Campos Acevedo, Qinghua Wang
doi: https://doi.org/10.1101/2021.04.05.438537
Most importantly, the inhibitor was equally effective against other coronavirus spike proteins that shared as low as 35% amino-acid sequence identity, underscoring its extreme tolerance to mutations. The small-sized inhibitor would also allow simple delivery by, for instance, nasal spray. We expect the inhibitor reported here to be an invaluable aid to help end COVID-19 pandemic. Furthermore, the use of a partial native sequence or its homologues to interfere with the functions of the native protein represents a novel concept for targeting other viral proteins in combating against important viral pathogens.
https://www.biorxiv.org/content/10.1101/2021.04.05.438537v1
François Naef
Experience
Musée international de la Croix-Rouge et du Croissant-Rouge, Genève
Director
Company Name Musée international de la Croix-Rouge et du Croissant-Rouge, Genève
Dates Employed Jan 2017 – Present
Employment Duration4 yrs 5 mos
Fondation Eclosion
Director
Company Name Fondation Eclosion
Dates Employed Jan 2017 – Present
Employment Duration4 yrs 5 mos
Waypoint Capital
Group General Counsel and Head of Human Resources
Company Name Waypoint Capital
Dates Employed Apr 2014 – Present
Employment Duration7 yrs 2 mos
Location Région de Genève, Suisse
Merck Serono S.A.
Chairman of the Board
Company Name Merck Serono S.A.
Dates Employed Jan 2012 – Mar 2014
Employment Duration2 yrs 3 mos
Location Région de Genève, Suisse
Merck KGaA
Group General Counsel
Company Name Merck KGaA
Dates Employed Jul 2009 – Mar 2014
Employment Duration4 yrs 9 mos
linkedin
Francois Naef
Chairman of the Board of Directors
Merck Serono
https://merckbiopharmaindia.wordpress.com/tag/francois-naef/
Continue from last post!
From Iran on virosomes
Table 2. A list of virosome based formulation.
SARS-CoV-2 Virosomes HA, NA, s protein Phase I/II Injection.(NO INFO)
HIV-1 Virosomes, HA, NA, P1, gp41, TLR7/81 New GMP Mucose [57]
M. Amacker, C. Smardon, L. Mason, J. Sorrell, K. Jeffery, M. Adler, F. Bhoelan, O. Belova, M. Spengler, B. Punnamoottil, M. Schwaller, O. Bonduelle, B. Combadière, T. Stegmann, A. Naylor, R. Johnson, D. Wong, S. Fleury
New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes
npj Vaccines, 5 (1) (2020), p. 41
View Record in ScopusGoogle Scholar
Respiratory Syncytial Virus (RSV)Virosomes, HA, NA, RSV fusion proteins Under GMP8 IM [58]
J. Lederhofer, J. van Lent, F. Bhoelan, Z. Karneva, A. de Haan, J.C. Wilschut, T. Stegmann
Development of a Virosomal RSV vaccine containing 3D-PHAD® adjuvant: formulation, composition, and long-term stability
Pharm. Res., 35 (9) (2018), Article 172
View Record in ScopusGoogle Scholar
https://www.sciencedirect.com/science/article/pii/S0141813021007601?via%3Dihub
Gilles Della Corte
Founder at Dellmed Consulting
François Naef
Group General Counsel at WayPoint Capital LLC
Ernesto Bertarelli
Co-Founder at Gurnet Point Capital LLC
https://relationshipscience.com/connections/gilles-della-corte-122192458
https://www.nasdaq.com/press-release/relief-appoints-gilles-della-corte-m.d.-as-chief-medical-officer-2020-09-04
Julia Lederhofer
Postdoctoral Researcher at National Institute of Allergy and Infectious Diseases (NIAID)
New Results
Structure-based design of stabilized recombinant influenza neuraminidase tetramers
Influenza virus neuraminidase (NA) is a major antiviral drug target and has recently reemerged as a key target of antibody-mediated protective immunity.
https://www.biorxiv.org/content/10.1101/2021.05.17.444468v1
Influenza vaccines: The virosome concept - ScienceDirect
www.sciencedirect.com › science › article
Feb 21, 2009 · Current influenza vaccines are mostly inactivated formulations, consisting of either split virus or subunit antigen, i.e. isolated haemagglutinin (HA) and neuraminidase (NA). The vaccines are trivalent preparations, containing antigens from two influenza A virus strains and one B strain, as recommended each year by the WHO. 1.2.
Influenza vaccines: The virosome concept
Author links open overlay panel Jan Wilschut
Department of Medical Microbiology, Molecular Virology Section, University Medical Center Groningen, University of Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands
Available online 25 December 2008
https://www.sciencedirect.com/science/article/abs/pii/S0165247808002551
HER-Vaxx Re-Formulation Shows Dramatic Ten-Fold Increase in ...
www.asx.com.au › asxpdf › 20150420
immunizations), compared with the earlier virosome-based formulation of HER-Vaxx. HER-Vaxx stimulates a polyclonal antibody response to HER-2/neu, the oncogene which is targeted by the currently used monoclonal antibody Herceptin®. Further, on Friday 17th April, the Company filed new patent applications around the new
https://www.asx.com.au/asxpdf/20150420/pdf/42xzdym1slg09p.pdf
Our PD-1 B-cell immunotherapy, known as PD1-Vaxx, aims to induce the body to produce polyclonal antibodies that block PD-1 signalling, and thus produce an anticancer effect similar to Keytruda, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies, that have transformed treatment for a range of cancers. PD1-Vaxx has shown encouraging potential in preclinical studies, including outperforming an industry-standard mouse anti-PD-1 antibody in a mouse model of colorectal cancer.
We have two HER2 B-cell immunotherapies in clinical trials, one from Ohio State University (OSU) known as B-Vaxx in Phase 2 clinical trial, and another from the University of Vienna Medical School known as HER-Vaxx in a Phase 1b/2 clinical trial. In earlier Phase I studies, both immunotherapies showed that they stimulated production of polyclonal antibodies against HER2, with encouraging indications of efficacy, thus providing proof of concept (PoC) for the B-cell immuno-therapy technology as well as suggesting therapeutic potential in HER2+ cancers.
https://www.imugene.com/technologies-introduction
Everyone knows were HER-VAXX came from MYMX